Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 4,067.4	$ 4,520.5	$ 12,351.0	$ 13,482.3
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,540.3	2,803.1	7,577.5	8,229.4
Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	320.2	332.0	1,065.8	993.7
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,206.9	1,385.4	3,707.7	4,259.2
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	420.4	410.0	1,266.1	1,272.9
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	189.3	198.4	600.1	635.9
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	156.5	175.6	483.9	555.9
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	117.0	138.0	361.9	412.4
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	114.4	129.5	309.7	337.3
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	82.2	86.0	253.4	257.3
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	64.2	79.5	215.4	239.6
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	53.1	61.3	188.7	208.8
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	76.4	81.1	226.5	231.7
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	51.0	55.8	146.7	172.0
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	39.4	49.5	125.3	147.5
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	38.3	47.6	115.5	141.5
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	38.6	35.0	138.0	129.9
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	53.4	39.4	146.1	118.1
Influvac ®
Disaggregation of Revenue [Line Items]
Net sales	159.3	161.2	178.3	165.3
Developed Markets | Brands
Disaggregation of Revenue [Line Items]
Net sales	1,327.7	1,522.7	3,931.8	4,350.5
Developed Markets | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	295.0	305.1	986.1	926.4
Developed Markets | Generics
Disaggregation of Revenue [Line Items]
Net sales	808.8	828.1	2,468.8	2,591.0
Greater China | Brands
Disaggregation of Revenue [Line Items]
Net sales	571.9	566.8	1,687.9	1,706.9
Greater China | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	0.2	0.0	0.5	0.0
Greater China | Generics
Disaggregation of Revenue [Line Items]
Net sales	1.9	0.0		2.1
JANZ | Brands
Disaggregation of Revenue [Line Items]
Net sales	211.6	299.1	703.7	878.5
JANZ | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	10.9	13.2	33.3	31.9
JANZ | Generics
Disaggregation of Revenue [Line Items]
Net sales	160.5	193.0	496.9	577.8
Emerging Markets | Brands
Disaggregation of Revenue [Line Items]
Net sales	429.1	414.5	1,254.1	1,293.5
Emerging Markets | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	14.1	13.7	45.9	35.4
Emerging Markets | Generics
Disaggregation of Revenue [Line Items]
Net sales	235.7	364.3	735.0	1,088.3
Operating Segment | Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	2,431.5	2,655.9	7,386.7	7,867.9
Operating Segment | Greater China
Disaggregation of Revenue [Line Items]
Net sales	574.0	566.8	1,695.4	1,709.0
Operating Segment | JANZ
Disaggregation of Revenue [Line Items]
Net sales	383.0	505.3	1,233.9	1,488.2
Operating Segment | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	$ 678.9	$ 792.5	$ 2,035.0	$ 2,417.2